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Background: Many patients with acromegaly require medical treatment that includes somatostatin analogs (SSAs).
Long-acting SSA formulations are widely used, due in part to increased patient convenience and increased treatment
adherence vs daily medications. Although medication compliance can be poor in patients with chronic conditions,
adherence and persistence with these SSAs in patients with acromegaly has not been evaluated. This analysis
utilized claims data to estimate treatment adherence and persistence for lanreotide depot and long-acting octreotide
in this population.
Methods: This retrospective analysis used the MarketScan® database (~100 payors, 500 million claims in the US),
which was searched between January 2007 and June 2012 to identify patients with acromegaly taking either
lanreotide depot or long-acting octreotide. Patients switching treatments were excluded. Treatment adherence
was assessed using medication possession ratio (MPR; number of doses dispensed in relation to dispensing period;
≥80% is considered adherent), injection count, and treatment time. Persistence was estimated by Kaplan-Meier
analyses and Cox proportional hazards modeling. A washout period, defined as no acromegaly-related prescription
activity 180 days prior to the index date, was employed to minimize effects of prior therapy and focus on patients
more likely to be treatment-naïve.
Results: Altogether 1308 patients with acromegaly receiving a single SSA for treatment (1127 octreotide, 181
lanreotide) who had not switched treatments were identified. Mean MPR in patients with a 180-day washout
(n = 663) was 89% for those receiving octreotide (n = 545) and 87% for those receiving lanreotide (n = 118).
Median number of days on therapy was 169 (95% CI 135–232) for octreotide patients and 400 (95% CI 232–532)
for lanreotide patients. The point estimate of the Cox proportional hazard ratio for stopping treatment was 1.385 for
octreotide vs lanreotide (95% CI 1.079–1.777), suggesting a 38.5% increased risk for stopping octreotide before
lanreotide.
Conclusions: Treatment adherence was similarly good for both injectable SSA treatments studied, at 87% or
greater. Persistence was greater with lanreotide than octreotide and the risk of discontinuing therapy was lower with
lanreotide than octreotide. Further studies to determine factors leading to these differences in persistence or to
predict discontinuation of therapy may aid in clinical management of these patients.
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Acromegaly is a disorder caused by hypersecretion of
growth hormone (GH). It has an incidence of approxi-
mately 3 per million per year, a prevalence of 40–1000
per million, a mean age at diagnosis of 44 years, and an
equal distribution between men and women [1–3].
Common clinical features of acromegaly include acral
enlargement, maxillofacial changes, excessive sweating,
arthralgias, headache, hypogonadal symptoms, visual
defects, fatigue, and weight gain [4]. The most frequent
cause of acromegaly is a GH-secreting pituitary adenoma,
which can be evaluated via magnetic resonance imaging
(MRI) once clinical signs and biochemical evidence of GH
hypersecretion are determined [5]. The primary therapy
for most patients is surgery, which will immediately
lower the level of GH [1, 5, 6]. The remission rate for
resected microadenomas and macroadenomas is >85
and 40–50%, respectively, with a 5-year recurrence rate
of 2–8% [6].
For patients who are poor candidates for surgery, who
have unresectable tumors, or who have incomplete
resection of their tumor and persistent disease, the
Endocrine Society recommends therapy with either a
somatostatin analog (SSA) or pegvisomant, a GH recep-
tor antagonist; for patients with mild symptoms and
modest elevations in insulin-like growth factor (IGF-1),
which is the main GH-dependent growth factor in-
creased in patients with acromegaly, the recommenda-
tions is a dopamine agonist [1, 6]. The American
Association of Clinical Endocrinologists recommends
therapy with SSAs following surgery in patients with
residual disease, dopamine agonists in patients with mild
biochemical activity, and pegvisomant in patients with
incomplete responses to SSA or dopamine agonists [5].
Lanreotide and octreotide are long-acting SSAs given as
injections every 4 weeks as long-term therapy for
patients with an inadequate response to surgery or who
are not candidates for surgery [7–9]. The long-acting
formulations circumvent the daily injections required
with other agents used in the treatment of acromegaly,
such as pegvisomant [6]. There is no clear benefit on
surgical outcomes or perioperative morbidity/mortality
with use of SSAs prior to surgery [10].
Effective therapy requires adherence, defined as taking
a medication at the time it is prescribed, and persistence,
defined as the duration between starting and discon-
tinuing a medication [11, 12]. For retrospective analyses,
adherence is defined as the number of doses dispensed in
relation to the dispensing period, or the medication pos-
session ratio (MPR) [12]. Unfortunately, adherence and
persistence are often difficult to maintain in patients
with chronic conditions, with an estimated nonadher-
ence rate of 25–50% across multiple chronic conditions
[13]. The adherence and persistence for lanreotide andlong-acting octreotide in patients with acromegaly has
not been established, and therefore the primary objective
of this analysis was to determine the adherence and
persistence of SSAs in patients with acromegaly using a
retrospective database of pharmacy claims to reflect
real-world clinical practice. For this analysis, adherence
was measured by MPR and persistence was estimated
by Kaplan-Meier and Cox proportional hazards modelling.
This analysis also investigated the effect of a treatment
washout period on both adherence and persistence.
Methods
Study design
This retrospective analysis, conducted in 2013, used the
Truven Health Analytics MarketScan® database, which
links paid claims and encounter data for more than 100
payers and 500 million claims the United States. The
database includes commercial claims and encounters
(CCAE) from active employees, early retirees, COBRA
continuees, and dependents insured by employer-
sponsored plans. The number of patients captured in
the Truven database was not known. The database was
reviewed for the period between January 2007 and June
2012 to identify medical encounters due to acromegaly
and patients with acromegaly receiving either lanreotide
depot (Somatuline® depot, Ipsen Biopharmaceuticals,
Inc., Basking Ridge, NJ, USA) or octreotide long-acting
release (Sandostatin® LAR, Novartis Pharmaceuticals,
East Hanover, NJ, USA). All dosages were included in
the analysis. Patients were assumed to be receiving the
proper dosage and expected to continue with therapy.
Medical claims with an ICD-9 diagnosis code for acro-
megaly or a pharmacy claims for lanreotide, octreotide,
or pegvisomant were included in the initial scan. The
ICD-9 code included was 253.0. Because the analysis is a
by-product of a market share analysis, pegvisomant was
initially included in the persistence analysis, but was
removed later in the analysis because it belongs to a dif-
ferent drug class. All claims within the database were
unique with no duplicates. Each claim could be sepa-
rated into multiple line level entries. Patients known to
have switched SSA treatments within the time of the
analysis were excluded. Data unavailable for SSA injec-
tions given prior to the start of the data collection
period, and thus some patients may have been treated
previously with another therapy. To exclude the effect of
any SSA injections that may have been administered
prior to the start of the data collection period, a 180-day
washout period was used. During the washout period,
patients were not allowed to take acromegaly-related
prescriptions, but were permitted to take other medica-
tions. The washout period was defined as the number of
days between the initial occurrence of the patient in the
database and the first injection of an SSA. Use of the
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likely to be treatment-naive patients.Statistical analyses
Treatment adherence was assessed for each patient by
determining the MPR. Patients were defined as adherent
if the amount of medication provided to the patient
covered at least 80% based on days’ supply of medica-
tion divided by the number of days the patient should
be consuming the medication, using the equation
MPRi ¼ NIi  1ð Þ  30= TLi  T1ið Þ where NI was the
total number of injections for patient I, and where T1
and TL were the times for the first injection and last
injection, respectively. A factor of 30 was introduced as
the sum of 28 days of treatment per injection with a 2-day
grace period between refills.
Persistence to treatment was analyzed using survival
analysis, a time series statistical method used to model
time-to-event data [14]. For this study, a persistent event
was defined as the first occurrence of a patient more
than 15 days overdue for injection. The persistence was
calculated as S tð Þ ¼ Pr T > tð Þ ¼ R∞t f uð Þdu ¼ 1 F tð Þ
where S(t) was the survival function, Pr was probability,
T was a random variable denoting the time of the event,
t was a period of time, ƒ(u) was the density function and
F(t) was the cumulative distribution function. The
hazard function or probability of an event occurrence,
λ(t), was calculated as λ tð Þ ¼ limdt→0 Pr t≤T<tþdtjT≥tð Þdt ¼ f tð ÞS tð Þ
¼ S′ tð ÞS tð Þ where Pr was the probability of event occurrence
and ƒ(t) was the lifetime density function.
This study applied a non-parametric Kaplan-Meier
model and a semi-parametric Cox proportional hazards
model. For the Kaplan-Meier model, the patient was
considered to have an event if not treated within 30 days
of the last treatment. Patients were right-censored if the
database stopped capturing the patient’s data <30 days
from the last injection. Whether patients were treated
with an extended schedule of lanreotide, as Food and
Drug Administration (FDA)-approved, was not considered
for the analysis. The criteria for measuring persistence
was applied regardless of whether a patient was on an
extended dosing interval. The extended dosing interval is
FDA-approved only for lanreotide, so a comparative ana-
lysis for the proportion of adopted extended schedules
between octreotide and lanreotide patients could not be
performed. The study did not capture the relation of SSA
treatment adherence with radiation therapy. The Kaplan-
Meier method could fully utilize information provided by
right-censored data. Median survival time was the point at
which 50% of the patients were still adherent to treatment.
Median survival time could be directly read from the
Kaplan-Meier curve.The proportional hazards model attributed the survival
time to one or more contributing factors, with the actual
hazard calculated from a baseline hazard model λ0 and
exponent from risk factors with treatment with octreotide
or lanreotide as the risk factors with the equation:
λ tjXð Þ ¼ λ0 tð Þ exp β1X1 þ⋯þ βpXp
 
¼ λ0 tð Þ exp β′X
 
.
The relative risk of stopping treatment or hazard ratio
(HR) was estimated from the model, with a HR >1
indicating an increased risk of stopping treatment, a
HR =1 indicating an equal risk of stopping treatment,
and a HR <1 indicating a reduced risk of stopping
treatment.Results
Patients
The search of the MarketScan database between January
2007 and June 2012 identified 1632 unique patients
treated for acromegaly with octreotide, lanreotide, or
pegvisomant, (Fig. 1). Of these patients 1459 received a
single type of therapy, and 1308 who had not switched
medications received a long-acting SSA (1127 octreotide,
181 lanreotide). There were 17,827 prescriptions for
octreotide, pegvisomant, or lanreotide, with 3395 of
these prescriptions for outpatient injections of octreo-
tide, lanreotide, or pegvisomant associated with a diag-
nosis code for acromegaly. No inpatient treatment with
these medications for acromegaly was identified. The
number of patients identified in the longitudinal claims
database was not evenly distributed over the total
period of follow-up (Fig. 2). Limited demographic
information was available from the database search,
but the age and gender were similar for both treatment
cohorts and independent of the inclusion of the wash-
out period (Table 1).Adherence to lanreotide and octreotide in patients with
acromegaly
Descriptive statistics for the number of injections, treat-
ment time, and MPR were calculated for each treatment
group (Tables 2 and 3). The MPR for all patients receiving
octreotide or lanreotide (n = 1308) was 85 and 87%, re-
spectively, for those receiving octreotide and lanreotide.
The MPR for patients with a 180-day washout period
(n = 663) was 89 and 87%, respectively, for those receiving
octreotide and lanreotide, suggesting no effect of the
washout period on adherence to therapy with an SSA. In
the analysis of adherence outcomes in all patients
(Table 2), there were no differences in the number of
injections (10.8 octreotide vs 11.1 lanreotide) or mean
time of treatment (418.5 vs 383.8). In the analysis of
patients with a washout period (Table 3), there were fewer



























Fig. 1 Patient selection. *Pegvisomant was excluded from the analysis because it is not a somatostatin analog and the mode of treatment (daily
injection) was not considered comparable to that of octreotide and lanreotide (monthly injection) for this study
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vs 351.8 days).
Persistence with lanreotide and octreotide in patients
with acromegaly
The mean persistence, measured by Kaplan-Meier ana-
lysis, was 379 days (95% CI 325, 430) for all patients










































Fig. 2 Distribution of patients identified in the database throughout the stall patients receiving lanreotide (Fig. 3, n = 1308). When
measured by Kaplan-Meier analysis with the 180-day
washout, the mean persistence was 169 days (95% CI
135, 232) for patients receiving octreotide and 400 days
(95% CI 232, 532) in patients receiving lanreotide (Fig. 4,
n = 663). In all patients, a Cox proportional hazards
model indicated no difference in the likelihood of dis-
continuing either lanreotide or octreotide (HR: 1.164;20 660 900
st Injection Date-First Enroll Date
1140 1380 1620 1860
udy period
Table 1 Age and gender for patients with acromegaly receiving octreotide or lanreotide
All patients Patients with a 180-day washout period
Therapy Variable N Mean SD N Mean SD
Octreotide Age at first injection (yr) 1127 50.6 11.1 545 51.4 11.2
% of male patients 1127 45.9% 0.5 545 48.1% 0.5
Lanreotide Age at first injection (yr) 181 45.9 11.9 118 45.7 11.7
% of male patients 181 45.9% 0.5 118 44.9% 0.5
N sample size, SD standard deviation
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Cox proportional hazard model showed a significant
increase in risk of discontinuing octreotide compared
with lanreotide (HR: 1.381; p = 0.011) (Fig. 6).Discussion
We found that the risk of discontinuing octreotide was
greater than lanreotide in this analysis of “real world” ac-
romegaly data. The potential implications are important,
since adherence and persistence are necessary for these
drugs to work effectively. The use of the MarketScan
database enables a longer-term assessment of adherence
in a less structured setting vs clinical trials. Patients
enrolled in the three trials that led to the approval of
octreotide were treated for either 12 or 28 months (52
or 112 weeks) and patients enrolled in the clinical trials
with lanreotide were treated for either 48 or 52 weeks
[8, 9]. In this retrospective analysis, the median persist-
ence for treatment was 169 days (5.6 months) with
long-acting octreotide and 400 days (57.1 weeks) with
lanreotide depot. Why treatment persistence was differ-
ent between the two drugs in this setting is worth
further exploration.
This analysis utilized the MarketScan database to
retrospectively study the adherence and persistence of
treatment with either lanreotide or octreotide in patients
with acromegaly. While the initial data search included
patients being treated with pegvisomant, a daily GH
agonist, there were ultimately only 1308 patients identi-
fied who had been treated with a single SSA, with only
181 of these patients taking lanreotide over the 5.5-yearTable 2 Treatment adherence outcomes in all patients with acrome
Treatment N Variable N
Octreotide 1127 Treatment time (days) 1127
Number of injections 1127
MPR (%) 891
Lanreotide 181 Treatment time (days) 181
Number of injections 181
MPR (%) 155
Only one injection was logged and used for treatment time calculation
N sample size, SE standard error, MPR medication possession ratiodata collection period before the analysis was limited
with a washout period.
This analysis excluded patients who had received more
than one therapy for treatment of acromegaly. It may be
worth considering including these patients in future
studies, particularly since this may help explain differ-
ences in adherence and persistence, such as reasons for
discontinuing an SSA or starting a different one. The
current analysis establishes a comparison of adherence
and persistence in a set of patients who are likely receiv-
ing first-line therapy with an SSA due to the exclusion
of more than one therapy and inclusion of a washout
period. Using these methods for analysis of adherence
and persistence with a more inclusive dataset would also
be more reflective of actual clinical practice and increase
the number of patients in the analysis.
The washout period was included in this analysis in
order to minimize the likelihood of an effect of any SSA
injections prior to the start of the data collection period.
There is no standard length for a washout period with
previous reimbursement claim analysis studies, which have
used a 6-month or 12-month washout period [15, 16]. A
longer washout period more effectively isolates treatment
effects; however, this is at the cost of reducing the sample
size. For this analysis, a washout period of 180 days was
selected to improve data quality, which significantly
decreased the sample size.
An interesting finding from this analysis was that the
inclusion of a washout period altered the persistence or
likelihood to discontinue treatment with a SSA in the
absence of an effect on adherence. This effect was not
on the adherence, the parameter more temporallygaly receiving octreotide or lanreotide
Mean SE Minimum Maximum
418.5 14.9 0 1819
10.8 0.4 1 68
87 4 0.06 30
383.8 28.1 0 1454
11.1 0.8 1 49
85 3 0.12 3.8
Table 3 Treatment adherence outcomes in patients with acromegaly receiving octreotide or lanreotide with 180-day washout
period
Treatment N Variable N Mean SE Minimum Maximum
Octreotide 545 Treatment time (days) 545 254.7 14.5 0 1563
Number of injections 545 7.21 0.4 1 63
MPR (%) 389 89 3 0.06 10
Lanreotide 118 Treatment time (days) 118 351.8 34.2 0 1454
Number of injections 118 10.2 0.9 1 49
MPR (%) 99 87 4 0.13 3.8
N sample size, SE standard error, MPR medication possession ratio
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ences of previous therapies. The effect of the washout
was on how long patients remained on therapy. In this
analysis, there was no difference in adherence, measured
by MPR, between patients receiving lanreotide and
octreotide regardless of the inclusion of a washout
period. In contrast, the persistence of therapy with lan-
reotide and a decrease in the likelihood of discontinuing
lanreotide was only observed when a 180-day washout
was incorporated. Possible differences between lanreo-
tide and octreotide that may impact adherence and
long-term persistence include a subcutaneous route of
administration for lanreotide, an intramuscular injection
for octreotide, and the availability of lanreotide in a pre-
filled syringe compared with the need to dilute octreo-
tide prior to injection [8, 9]. While these factors may
confer a clinical advantage favoring lanreotide in some
patients, it is not clear from the retrospective data ana-
lysis reported here that these factors would be importantFig. 3 Kaplan Meier analysis of treatment persistence with octreotide vs lan
at risk. Survival indicates probability of patients continuing treatment. LAN lfor differences in persistence of SSA therapy due to
inclusion of a washout period. The reason for this
washout-associated difference in persistence should be
explored. Further, addition of clinical information about
reasons for discontinuation of therapy, any further ther-
apy the patients who discontinue therapy with an SSA
may receive, and persistence to the second therapy may
be useful for clinicians as they chose an initial and
second therapy for their patients.
When determining the clinical impact of this analysis,
the primary limitations include the number of patients
included in the analysis, the exclusion of patients who
had switched therapy, and the lack of clinical data from
these patients. Acromegaly is a rare disease, and the ana-
lysis of the database over a 5.5 year period only captured
1,308 patients who had received a single SSA. The num-
ber of covered lives in the database was not available,
but the number is less than what would be expected



































Fig. 4 Kaplan-Meier analysis of treatment persistence with octreotide or lanreotide, patients with 180-day washout period (n = 663). Numbers above
axis indicate subjects at risk. Survival indicates probability of patients continuing treatment. LAN lanreotide; OCT octreotide
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tions on average may be that patients changed medical
plans or medical plans stopped reporting data to Truven.
The use of the 180-day washout period and the exclu-
sion of patients who switched therapies contributed to
the low accrual. The combination of adherence and per-
sistence data with clinical information may lead to inter-
esting findings impacting the use of each SSA if drug



















Fig. 5 Persistency chart (proportional hazards model) for octreotide vs lanr
continuing treatment. Hazard ratio (risk of discontinuing treatment) for octadherence and persistence due to a need to change ther-
apy. Finally, inclusion of clinical data, particularly at the
time that drug was discontinued, could provide very
important information to understand the finding of this
analysis. In these patients, the adherence was not signifi-
cantly different for the two drugs and this likely reflects
similar tolerance. In the absence of clinical data, it is
unclear if the increased persistence is good or bad. A




eotide, all patients (n = 1308). Survival indicates probability of patients






















Fig. 6 Persistency chart (proportional hazards model) for octreotide vs lanreotide, patients with 180-day washout period (n = 663). Survival indicates
probability of patients continuing treatment. Hazard ratio (risk of discontinuing treatment) for octreotide vs lanreotide: 1.381; p = 0.011
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longer persistence on lanreotide due to less effectiveness
to control the acromegaly would support use of octreo-
tide. The incorporation of clinical data would answer
these questions. Otherwise, the persistence is longer in
patients receiving lanreotide in the setting of a washout
period, but while the clinical impact can be inferred, it
isn’t clear.
This analysis was a by-product of a market share ana-
lysis so the octreotide and lanreotide patients could not
be directly compared. Without the addition of a matching
step using propensity scores, it could only be assumed that
the octreotide and lanreotide treatment groups were com-
parable. Because we identified patients by diagnosis codes
and treatments, there was no indication of whether the
patients were on extended schedules or in withdrawal in
the claim database. There was no evidence the extended
schedule or withdrawal period were happening dispropor-
tionally between two treatment groups. Therefore, we did
not stratify on that variable, which may be a potential con-
founder in the interpretation of the results.
Conclusions
This study has shown that a retrospective database can
be used to determine adherence to therapy, measured by
MPR, and to compare the persistence to treatment by
modelling with Kaplan-Meier and Cox proportional
hazards modelling in patients receiving SSAs for acro-
megaly. In this analysis, patients receiving lanreotide
and octreotide had similar adherence to therapy, with
an increase in persistence for patients receivinglanreotide compared with octreotide when a washout
period was included. Further studies are warranted to
determine what factors lead to increased time on therapy
to guide clinicians treating this disease.
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